Hepatitis B Study

In this trial, we are evaluating the safety and pharmacokinetics of an experimental new medicine that is being developed to protect people from being infected by the hepatitis B virus.

Hepatitis B virus (HBV) has infected more than 2 billion people worldwide, with a particularly high incidence in China. The current treatment options are suboptimal, due to the development of drug resistance, and toxicity.

If you meet the criteria for this study and would like more information, register below or call 1800 727 874.

– Be a healthy male, or healthy female who is not pregnant and who is using highly effective contraception.
– Aged 18-45 (inclusive)
– have a Body Mass Index (BMI) >18 and <30 kg/m2